Strikingly, tumor harboring these alterations in EGFR are commonly associated with pro-oxidant tumor microenvironment, opening a new window into the therapeutic armamentarium to use PROTAC against lung cancer. The gene discussed is EGFR; the disease is lung carcinoma.